Advanced search
Publication Cover
Journal of Medical Economics Volume 15, 2012 - Issue 1
Submit an article Journal homepage
639
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness of prasugrel in a US managed care population

Josephine A. MauskopfRTI Health Solutions, Research Triangle Park NC, USACorrespondence[email protected]
,
Jonathan B. GrahamRTI Health Solutions, Research Triangle Park NC, USA
,
Jay P. BaeEli Lilly & Company, Indianapolis, IN, USA
,
Krishnan RamaswamyDaiichi Sankyo Inc., Parsippany, NJ, USA
,
Anthony J. ZagarEli Lilly & Company, Indianapolis, IN, USA
,
Elizabeth A. MagnusonSt Luke’s Mid America Heart and Vascular Institute and the University of Missouri-Kansas City School of Medicine Kansas City, MO, USA
,
David J. CohenSt Luke’s Mid America Heart and Vascular Institute and the University of Missouri-Kansas City School of Medicine Kansas City, MO, USA
&
Eric S. MeadowsEli Lilly & Company, Indianapolis, IN, USA
 show all
Pages 166-174 | Accepted 31 Oct 2011, Published online: 18 Nov 2011

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

William H. Olson, Yi-Wen Ma, Concetta Crivera, Jeff Schein, Patrick Lefebvre, François Laliberté, Katherine Dea, Guillaume Germain & Scott M. Lynch. (2015) Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. Journal of Medical Economics 18:12, pages 1074-1084.
Read now
Nicholas B. Norgard & James J. DiNicolantonio. (2013) Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. Postgraduate Medicine 125:4, pages 91-102.
Read now
Andrew Davies, Ameet Bakhai, Claude Schmitt, Annabel Barrett, Peita Graham-Clarke & Mark Sculpher. (2013) Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of Medical Economics 16:4, pages 510-521.
Read now

Articles from other publishers (9)

Olubadewa A. Fatunde & Sherry-Ann Brown. (2020) The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology. International Journal of Molecular Sciences 21:2, pages 604.
Crossref
Bastian Wein, Michael Coslovsky, Reza Jabbari, Søren Galatius, Matthias Pfisterer & Christoph Kaiser. (2017) Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. International Journal of Cardiology 248, pages 20-27.
Crossref
Kibum KimTodd A. LeeDaniel R. TouchetteRobert J. DiDomenicoAmer K. ArdatiSurrey M. Walton. (2017) Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy 23:1, pages 57-63.
Crossref
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Nigel Fleeman, Joanne McEntee, Yenal Dundar, Marty Richardson & Michael Fisher. (2015) Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment 19:29, pages 1-130.
Crossref
Fotini Gialama, Evangelia Miloni & Nikos Maniadakis. (2014) Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome. PharmacoEconomics 32:11, pages 1063-1078.
Crossref
Maximilian H. M. Hatz, Reiner Leidl, Nichola A. Yates & Björn Stollenwerk. (2014) A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. PharmacoEconomics 32:4, pages 377-393.
Crossref
Victor L. Serebruany & Seth D. Fortmann. (2017) Viewpoint: “Underutilisation of novel antiplatelet agents – myths, generics, and economics”. Thrombosis and Haemostasis 112:07, pages 4-9.
Crossref
William S. Weintraub, Leonid Mandel & Sandra A. Weiss. (2013) Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations. PharmacoEconomics 31:11, pages 959-970.
Crossref
Katherine A. Lyseng-Williamson. (2012) Prasugrel: A Guide to Its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the US. American Journal Cardiovascular Drugs 12:3, pages 207-216.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.